173999-19-4

Basic information

• Product Name: 5-Bromo-N-methylpyridine-3-sulfonamide
• Synonyms: 5-Bromo-N-methylpyridine-3-sulfonamide;N-Methyl 5-bromopyridine-3-sulfonamide
• CAS NO: 173999-19-4
• Molecular Formula: C₆H₇BrN₂O₂S
• Molecular Weight: 251.1
• Mol File: 173999-19-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Bromo-N-methylpyridine-3-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-N-methylpyridine-3-sulfonamide(173999-19-4)
• EPA Substance Registry System: 5-Bromo-N-methylpyridine-3-sulfonamide(173999-19-4)

Safety Data

• Hazardous Substances Data: 173999-19-4(Hazardous Substances Data)

Usage

General Description

5-Bromo-N-methylpyridine-3-sulfonamide is a chemical compound that is commonly used in pharmaceutical research and development. It is a sulfonamide derivative, with a bromo substituent and a methylpyridine group. 5-Bromo-N-methylpyridine-3-sulfonamide has been studied for its potential pharmacological activities, including as an anti-bacterial and anti-cancer agent. Its structure and properties make it a valuable intermediate for the synthesis of various biologically active molecules. The compound's unique combination of functional groups and its potential for a wide range of applications make it an important target for chemical synthesis and drug discovery efforts.

Upstream product

• 42899-76-3 pyridine-3-sulfonyl chloride hydrochloride 
• 74-89-5 methylamine 
• 65001-21-0 5-bromopyridine-3-sulphonyl chloride 

Relevant articles and documents

Identification of Purines and 7-Deazapurines as Potent and Selective Type i Inhibitors of Troponin I-Interacting Kinase (TNNI3K)

A series of cardiac troponin I-interacting kinase (TNNI3K) inhibitors arising from 3-((9H-purin-6-yl)amino)-N-methyl-benzenesulfonamide (1) is disclosed along with fundamental structure-function relationships that delineate the role of each element of 1 for TNNI3K recognition. An X-ray structure of 1 bound to TNNI3K confirmed its Type I binding mode and is used to rationalize the structure-activity relationship and employed to design potent, selective, and orally bioavailable TNNI3K inhibitors. Identification of the 7-deazapurine heterocycle as a superior template (vs purine) and its elaboration by introduction of C4-benzenesulfonamide and C7- and C8-7-deazapurine substituents produced compounds with substantial improvements in potency (>1000-fold), general kinase selectivity (10-fold improvement), and pharmacokinetic properties (>10-fold increase in poDNAUC). Optimal members of the series have properties suitable for use in in vitro and in vivo experiments aimed at elucidating the role of TNNI3K in cardiac biology and serve as leads for developing novel heart failure medicines.

COMPOUNDS AND METHODS

Disclosed are compounds having the formula (I): wherein R1, R2, R3, R4, R5, and R6 are as defined herein, and methods of making and using the same.